Valeant Pharmaceuticals International Inc. says its US$11.1-billion friendly takeover bid for Salix Pharmaceuticals, Ltd. was successful, with about three-quarters of all Salix shares tendered by the deadline early Wednesday. Valeant's offer of US$173 in cash per Salix share defeated a rival bid from Dublin-based Endo International, which had offered a combination of stock and cash valued at about US$175 per share.